deferoxamine has been researched along with Anemia in 109 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Excerpt | Relevance | Reference |
---|---|---|
"Anemia is a well-defined complication of aluminum overload in chronic dialysis patients which may be present before other manifestations of aluminum toxicity are obvious." | 7.67 | The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. ( Alfrey, AC; Contiguglia, RS; Klein, MH; Miller, NL; Mishell, JL; Molitoris, BA; Seligman, PA; Shapiro, JI; Yuan, B, 1989) |
"Improvement of microcytic anemia after deferoxamine treatment is described in eight long-term dialysis patients with high serum aluminum concentration and other clinical signs of aluminum toxicity." | 7.67 | Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. ( Burnatowska-Hledin, M; Dombrouski, J; Mayor, G; Swartz, R, 1987) |
"All of 34 patients with untreated hemochromatosis had distinctly elevated values for deferoxamine-chelatable iron." | 5.26 | Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. ( Baggenstoss, AH; Baldus, WP; Dickson, ER; Fairbanks, VF, 1978) |
"The randomized comparison of deferasirox to deferoxamine for myocardial iron removal in patients with transfusion-dependent anemias (CORDELIA) gave the opportunity to assess relative prevalence and body distribution of iron overload in screened patients." | 5.20 | Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. ( Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Pennell, DJ; Piga, A; Porter, JB; Quebe-Fehling, E; Viprakasit, V; Yesilipek, A, 2015) |
" Recombinant erythropoietin alfa and darbepoetin alfa have been the mainstay of therapy for treating anemia associated with MDS." | 3.74 | The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. ( Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH, 2008) |
"The study population consisted of 26 Zambian children < 6 years of age who presented with cerebral malaria to a rural hospital in 1994 and who were treated with quinine for seven days." | 3.70 | Prolonged macrophage activation and persistent anaemia in children with complicated malaria. ( Biemba, G; Gordeuk, VR; Mabeza, GF; Thuma, PE; Weiss, G, 1998) |
"Anemia is a well-defined complication of aluminum overload in chronic dialysis patients which may be present before other manifestations of aluminum toxicity are obvious." | 3.67 | The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. ( Alfrey, AC; Contiguglia, RS; Klein, MH; Miller, NL; Mishell, JL; Molitoris, BA; Seligman, PA; Shapiro, JI; Yuan, B, 1989) |
"Improvement of microcytic anemia after deferoxamine treatment is described in eight long-term dialysis patients with high serum aluminum concentration and other clinical signs of aluminum toxicity." | 3.67 | Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. ( Burnatowska-Hledin, M; Dombrouski, J; Mayor, G; Swartz, R, 1987) |
"The iron-chelating agent deferoxamine (DF) was administered as a single dose and also daily over a prolonged period to evaluate availability of storage iron in dogs with induced anemia of inflammatory disease." | 3.66 | Anemia of inflammatory disease in the dog: availability of storage iron in inflammatory disease. ( Farver, TB; Feldman, BF; Kaneko, JJ, 1981) |
"Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints." | 2.44 | Chelation therapy for iron overload. ( Barton, JC, 2007) |
"Deferoxamine has been used effectively in clinical practice for more than 40 years." | 1.35 | Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias. ( Ault, P; Jones, K, 2009) |
"Here, we discuss a patient with primary myelofibrosis and related transfusion-dependent anemia who received chelation therapy with the once-daily oral iron chelator, deferasirox." | 1.34 | Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). ( Alberti, D; Angelucci, E; Deplano, S; Di Tucci, AA; Murru, R; Rabault, B, 2007) |
" More frequent dosing and/or a longer duration of HP treatment might produce greater reversal of the Al-induced toxicity and perhaps reveal more adverse effects than seen in this study." | 1.30 | Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. ( Dickey, KM; Fredenburg, AM; Hong, CB; Meurer, KA; Skinner, TL; Yokel, RA, 1997) |
" This treatment can enhance erythropoiesis without adverse effects." | 1.30 | Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects. ( Chen, JB; Hsu, KT; Lam, KK; Lee, CT; Liao, SC, 1999) |
" However, there was no correlation between the serum Al level and the dosage of aluminum hydroxide." | 1.28 | Effect of body iron stores on serum aluminum level in hemodialysis patients. ( Huang, CC; Huang, JY; Leu, ML; Lim, PS; Wu, MS, 1992) |
" The biochemical evidence of functional iron deficiency and the response to aluminum chelation therapy support the hypothesis that the inhibitory effect of aluminum on erythropoiesis is mediated by the interference of aluminum with the bioavailability of iron." | 1.28 | The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment. ( Donnelly, SM; Smith, EK, 1990) |
"All of 34 patients with untreated hemochromatosis had distinctly elevated values for deferoxamine-chelatable iron." | 1.26 | Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. ( Baggenstoss, AH; Baldus, WP; Dickson, ER; Fairbanks, VF, 1978) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 65 (59.63) | 18.7374 |
1990's | 24 (22.02) | 18.2507 |
2000's | 17 (15.60) | 29.6817 |
2010's | 1 (0.92) | 24.3611 |
2020's | 2 (1.83) | 2.80 |
Authors | Studies |
---|---|
Chen, MY | 1 |
Ou, SH | 1 |
Chen, NC | 1 |
Yin, CH | 1 |
Chen, CL | 1 |
Aydinok, Y | 1 |
Porter, JB | 2 |
Piga, A | 1 |
Elalfy, M | 1 |
El-Beshlawy, A | 1 |
Kilinç, Y | 1 |
Viprakasit, V | 1 |
Yesilipek, A | 1 |
Habr, D | 1 |
Quebe-Fehling, E | 1 |
Pennell, DJ | 1 |
Greenberg, PL | 1 |
Cosler, LE | 1 |
Ferro, SA | 1 |
Lyman, GH | 1 |
McLeod, C | 1 |
Fleeman, N | 1 |
Kirkham, J | 1 |
Bagust, A | 1 |
Boland, A | 1 |
Chu, P | 1 |
Dickson, R | 1 |
Dundar, Y | 1 |
Greenhalgh, J | 1 |
Modell, B | 2 |
Olujohungbe, A | 1 |
Telfer, P | 1 |
Walley, T | 1 |
Yap, J | 1 |
O'Connor, C | 1 |
Kirby, M | 1 |
Guindi, M | 1 |
Roberts, EA | 1 |
Barbieri, L | 1 |
Macrì, A | 1 |
Lupia Palmieri, G | 1 |
Aurizi, C | 1 |
Biolcati, G | 1 |
Ault, P | 1 |
Jones, K | 1 |
Fernandes, JL | 1 |
Fabron, A | 1 |
Verissimo, M | 1 |
Leitch, HA | 1 |
Vickars, LM | 1 |
Jensen, PD | 2 |
Jensen, FT | 2 |
Christensen, T | 2 |
Nielsen, JL | 2 |
Ellegaard, J | 1 |
Eiskjaer, H | 1 |
Baandrup, U | 1 |
REWALD, EF | 1 |
WOEHLER, F | 1 |
DE VRIES, SI | 1 |
GOUDSMIT, R | 1 |
SCHRETLEN, ED | 1 |
NORMAN, CS | 1 |
MARCACCI, M | 1 |
CICALA, P | 1 |
GUIDONE, M | 1 |
NAPPI, L | 1 |
DIMARTINO, G | 1 |
HILDNER, FJ | 1 |
MONTO, RW | 1 |
REBUCK, JW | 1 |
CARLOS, AG | 1 |
SOARES, AD | 1 |
REWALD, E | 1 |
SCURO, LA | 1 |
BROCCIA, G | 1 |
DOBRILLA, G | 1 |
TAGLIAMONTE, A | 1 |
KARSTOFT, H | 1 |
HWANG, YF | 1 |
BROWN, EB | 1 |
VENTURA, S | 2 |
BETTI, R | 1 |
PALUMBO, R | 1 |
SENIN, U | 1 |
CAPPELLETTI, M | 1 |
COLI, L | 2 |
WILKINSON, JF | 1 |
MOESCHLIN, S | 1 |
SCHNIDER, U | 1 |
RICHMOND, J | 1 |
ALBAHARY, C | 1 |
FIELDING, J | 1 |
BANNERMAN, RM | 1 |
MALPAS, JS | 1 |
WHITE, HC | 1 |
GEVIRTZ, NR | 1 |
TENDLER, D | 1 |
LURINSKY, G | 1 |
WASSERMAN, LR | 1 |
Franchini, M | 2 |
Gandini, G | 2 |
Veneri, D | 1 |
Aprili, G | 2 |
Schmidt, D | 1 |
Finke, J | 1 |
Kashiwagi, T | 1 |
Kurihara, S | 2 |
Ambrus, CM | 1 |
Stadler, I | 1 |
Toumbis, CA | 1 |
Stadler, A | 1 |
Anthone, S | 1 |
Anthone, R | 1 |
DeAlarcon, P | 1 |
Deshpande, G | 1 |
Conway, J | 1 |
Vladutiu, AO | 1 |
Ambrus, JL | 1 |
Barton, JC | 1 |
Di Tucci, AA | 1 |
Murru, R | 1 |
Alberti, D | 1 |
Rabault, B | 1 |
Deplano, S | 1 |
Angelucci, E | 1 |
Lawson, AA | 1 |
Owen, ET | 1 |
Mowat, AG | 1 |
Green, R | 1 |
Lamon, J | 1 |
Curran, D | 1 |
North, ML | 1 |
Lang, JM | 1 |
Bergerat, JP | 1 |
Giron, C | 1 |
Oberling, F | 1 |
Mayer, S | 1 |
Giordano, N | 1 |
Fioravanti, A | 1 |
Sancasciani, S | 1 |
Marcolongo, R | 1 |
Borghi, C | 1 |
Van der Weyden, MB | 1 |
Feldman, BF | 1 |
Kaneko, JJ | 1 |
Farver, TB | 1 |
Katz, AJ | 1 |
Halliday, JW | 1 |
Bassett, ML | 1 |
Goch, J | 1 |
Birgegård, G | 1 |
Danielson, BG | 1 |
Wikström, B | 1 |
Kozlov, AB | 1 |
Ostrachovitch, EA | 1 |
Afanas'ev, IB | 1 |
Ackrill, P | 1 |
Day, JP | 1 |
Yaqoob, M | 1 |
Ahmad, R | 1 |
McClelland, P | 1 |
Shivakumar, KA | 1 |
Sallomi, DF | 1 |
Fahal, IH | 1 |
Roberts, NB | 1 |
Helliwell, T | 1 |
Güngör, T | 1 |
Rohrbach, E | 1 |
Solem, E | 1 |
Kaltwasser, JP | 1 |
Kornhuber, B | 1 |
Salvarani, C | 1 |
Baricchi, R | 1 |
Lasagni, D | 1 |
Boiardi, L | 1 |
Piccinini, R | 1 |
Brunati, C | 1 |
Macchioni, P | 1 |
Portioli, I | 1 |
Yokel, RA | 1 |
Meurer, KA | 1 |
Hong, CB | 1 |
Dickey, KM | 1 |
Skinner, TL | 1 |
Fredenburg, AM | 1 |
Jurado, RL | 1 |
Biemba, G | 1 |
Gordeuk, VR | 1 |
Thuma, PE | 1 |
Mabeza, GF | 1 |
Weiss, G | 1 |
Wonke, B | 1 |
Aucella, F | 1 |
Vigilante, M | 1 |
Scalzulli, P | 1 |
Musto, P | 1 |
Prencipe, M | 1 |
Valente, GL | 1 |
Carotenuto, M | 1 |
Stallone, C | 1 |
Lee, CT | 1 |
Liao, SC | 1 |
Hsu, KT | 1 |
Lam, KK | 1 |
Chen, JB | 1 |
Girelli, D | 1 |
Lippi, G | 1 |
de Gironcoli, M | 1 |
Espósito, BP | 1 |
Breuer, W | 1 |
Slotki, I | 1 |
Cabantchik, ZI | 1 |
Pippard, MJ | 1 |
Callender, ST | 1 |
Weatherall, DJ | 1 |
Baldus, WP | 1 |
Fairbanks, VF | 1 |
Dickson, ER | 1 |
Baggenstoss, AH | 1 |
Nienhuis, AW | 1 |
Delea, C | 1 |
Aamodt, R | 1 |
Bartter, F | 1 |
Anderson, WF | 1 |
van Vugt, H | 1 |
van Gool, J | 1 |
Ladiges, NC | 1 |
Boers, W | 1 |
Vreugdenhil, G | 1 |
Feelders, RA | 1 |
Coppens, PJ | 1 |
de Leeuw, PW | 1 |
Marumo, F | 1 |
Huang, JY | 1 |
Huang, CC | 1 |
Lim, PS | 1 |
Wu, MS | 1 |
Leu, ML | 1 |
Verbeelen, D | 2 |
Padovese, P | 1 |
Gallieni, M | 1 |
Galmozzi, C | 1 |
Brancaccio, D | 1 |
Lowrey, S | 1 |
Casati, S | 2 |
Campise, M | 2 |
Ponticelli, C | 2 |
Castelnovo, C | 1 |
Cairo, MS | 1 |
Donnelly, SM | 1 |
Smith, EK | 1 |
Hosokawa, S | 1 |
Oyamaguchi, A | 1 |
Yoshida, O | 1 |
Bia, MJ | 1 |
Cooper, K | 1 |
Schnall, S | 1 |
Duffy, T | 1 |
Hendler, E | 1 |
Malluche, H | 1 |
Solomon, L | 1 |
Yuan, B | 1 |
Klein, MH | 1 |
Contiguglia, RS | 1 |
Mishell, JL | 1 |
Seligman, PA | 1 |
Miller, NL | 1 |
Molitoris, BA | 1 |
Alfrey, AC | 1 |
Shapiro, JI | 1 |
Van Wyck, DB | 1 |
Stivelman, JC | 1 |
Ruiz, J | 1 |
Kirlin, LF | 1 |
Katz, MA | 1 |
Ogden, DA | 1 |
de la Serna, FJ | 1 |
Praga, M | 2 |
Gilsanz, F | 1 |
Rodicio, JL | 2 |
Ruilope, LM | 2 |
Alcazar, JM | 1 |
Altmann, P | 1 |
Plowman, D | 1 |
Marsh, F | 1 |
Cunningham, J | 1 |
Tielemans, C | 1 |
Collart, F | 1 |
Wens, R | 1 |
Smeyers-Verbeeke, J | 1 |
Van Hooff, I | 1 |
Dratwa, M | 1 |
Abreo, K | 1 |
Brown, ST | 1 |
Sella, M | 1 |
Trapp, G | 1 |
Andrés, A | 1 |
de la Serna, J | 1 |
Nieto, J | 1 |
Estenoz, J | 1 |
Millet, VG | 1 |
Arnaiz, F | 1 |
Cuvelier, R | 1 |
Deceuninck, P | 1 |
Felipe, C | 1 |
Rivera, M | 1 |
Orofino, L | 1 |
Matesanz, R | 1 |
Ortuño, J | 1 |
Basile, C | 1 |
Scatizzi, A | 1 |
Grossman, SD | 1 |
Smith, LE | 1 |
O'Brien, AA | 1 |
Moore, DP | 1 |
Keogh, JA | 1 |
Mostert, LJ | 1 |
de Jong, G | 1 |
Koster, JF | 1 |
van Eijk, HG | 2 |
Swartz, R | 1 |
Dombrouski, J | 1 |
Burnatowska-Hledin, M | 1 |
Mayor, G | 1 |
Schafer, AI | 1 |
Rabinowe, S | 1 |
Le Boff, MS | 1 |
Bridges, K | 1 |
Cheron, RG | 1 |
Dluhy, R | 1 |
Andreoli, SP | 1 |
Dunn, D | 1 |
DeMyer, W | 1 |
Sherrard, DJ | 1 |
Bergstein, JM | 1 |
Kanz, L | 1 |
Arnold, H | 1 |
Löhr, GW | 1 |
Cartei, G | 2 |
Chisesi, T | 2 |
Cazzavillan, M | 2 |
Battista, R | 1 |
Barbui, T | 2 |
Dini, E | 2 |
Franchi, F | 1 |
Bobeck-Rutsaert, MM | 1 |
op den Kelder, AM | 1 |
Wiltink, WF | 1 |
Leijnse, B | 1 |
Stromeyer, G | 1 |
Turbina, NS | 1 |
Stojcevski, T | 1 |
Markovic, V | 1 |
Heilmeyer, L | 1 |
Harker, LA | 1 |
Funk, DD | 1 |
Finch, CA | 1 |
Hofvander, Y | 1 |
Jacobs, A | 1 |
Kaye, MD | 1 |
Trevett, D | 1 |
Cimino, R | 1 |
Quattrin, N | 1 |
Lee, GR | 1 |
Cartwright, GE | 1 |
Wintrobe, MM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Trial of Oral Nifedipine for the Treatment of Iron Overload[NCT00712738] | Phase 1 | 6 participants (Actual) | Interventional | 2008-06-20 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
12 reviews available for deferoxamine and Anemia
Article | Year |
---|---|
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferipro | 2009 |
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Topics: Aged; Anemia; Benzoates; Blood Component Transfusion; Chelation Therapy; Combined Modality Therapy; | 2009 |
ADVANCES IN TREATMENT OF DISEASES OF THE BLOOD.
Topics: Anemia; Anemia, Aplastic; Anemia, Pernicious; Bone Marrow Transplantation; Deferoxamine; Drug Therap | 1964 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Aluminum Hydroxide; Anemia; Bone Diseases, Metabolic; Contraindications; Deferoxamine; Dem | 2004 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferipron | 2007 |
The use of desferrioximine in dialysis-associated aluminium disease.
Topics: Aluminum; Anemia; Bone Diseases; Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Rena | 1993 |
Iron, infections, and anemia of inflammation.
Topics: Anemia; Bacteria; Bacterial Infections; Blood Transfusion; Carrier Proteins; Conalbumin; Deferoxamin | 1997 |
Bone disease in beta-thalassaemia major.
Topics: Anemia; beta-Thalassemia; Bone Diseases; Deferoxamine; Female; Humans; Male; Osteoporosis | 1998 |
Advances in the use of iron-chelating agents for the treatment of iron overload.
Topics: Adolescent; Adult; Anemia; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Heart; Hemochro | 1979 |
Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
Topics: Adolescent; Adult; Aged; Anemia; Ascorbic Acid; Deferoxamine; Drug Evaluation; Feces; Humans; Iron; | 1976 |
Clinical spectrum of iron overload, novel uses of iron chelators, and potential treatment of pediatric anemias with erythropoietin. Introduction.
Topics: Anemia; Chelation Therapy; Child; Deferoxamine; Erythrocyte Transfusion; Erythropoietin; Humans; Iro | 1990 |
[Use of desferal in treatment of sideroses of different origin. (Literature review)].
Topics: Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Animals; Bile; Child, Preschool; Deferoxamine; Hemo | 1968 |
7 trials available for deferoxamine and Anemia
Article | Year |
---|---|
Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Topics: Anemia; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload | 2023 |
Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Child; Deferoxamine; Female; Humans; Iron; Iron | 2015 |
Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias.
Topics: Adult; Aged; Anemia; Chelation Therapy; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; I | 2003 |
Clinical trial of desferrioxamine entrapped in red cell ghosts.
Topics: Adult; Aged; Anemia; Anemia, Aplastic; Blood Transfusion; Clinical Trials as Topic; Deferoxamine; Er | 1980 |
Treatment of erythropoietin-resistant anaemia with desferrioxamine in patients on haemofiltration.
Topics: Adult; Aged; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Female; Ferritins; Hemofiltratio | 1995 |
Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Carbohydrates; Chemistry, Pharmaceutical; Cohort | 2002 |
Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine.
Topics: Adult; Aged; Anemia; Clinical Trials as Topic; Creatinine; Deferoxamine; Erythrocyte Count; Erythroc | 1988 |
90 other studies available for deferoxamine and Anemia
Article | Year |
---|---|
Aluminum overload in the reverse osmosis dialysis era: does it exist?
Topics: Alkaline Phosphatase; Aluminum; Aluminum Compounds; Anemia; Calcium; Deferoxamine; Erythropoietin; H | 2022 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin al | 2008 |
Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
Topics: Adolescent; Anemia; Antiviral Agents; Chelation Therapy; Deferoxamine; Ferritins; Hemoglobinopathies | 2009 |
Association between porphyria cutanea tarda and beta-thalassemia major.
Topics: Adult; Anemia; beta-Thalassemia; Chloroquine; Deferoxamine; Female; Hepatitis C; Humans; Iron Overlo | 2009 |
Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
Topics: Anemia; Blood Transfusion; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Nu | 2009 |
Early cardiac iron overload in children with transfusion-dependent anemias.
Topics: Adolescent; Anemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Deferiprone; Defe | 2009 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Ove | 2009 |
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.
Topics: Adult; Aged; Anemia; Case-Control Studies; Chelation Therapy; Deferoxamine; Ferritins; Follow-Up Stu | 2003 |
[PREVENTION OF HYPERACTIVE ERYTHROPOIESIS AS A THERAPEUTIC CRITERION IN THALASSEMIA AND OTHER CORPUSCULAR ANEMIAS. PRELIMINARY NOTE].
Topics: Anemia; Blood Transfusion; Deferoxamine; Erythropoiesis; Humans; Hydroxamic Acids; Infant; Splenomeg | 1963 |
THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE.
Topics: Anemia; Anemia, Macrocytic; Deferoxamine; Diabetes Mellitus; Ferritins; Hemochromatosis; Hemoglobins | 1963 |
[TREATMENT OF IRON LOADING WITH DESFERRIOXAMINE].
Topics: Adolescent; Anemia; Anemia, Hemolytic; Anemia, Macrocytic; Child; Deferoxamine; Geriatrics; Hemoside | 1963 |
THE TREATMENT OF IRON OVERLOAD WITH DESFERRIOXAMINE B.
Topics: Anemia; Anemia, Aplastic; Blood Transfusion; Deferoxamine; Humans; Hydroxamic Acids; Iron Chelating | 1964 |
[INFLUENCE OF DESFERRIOXAMINE ON THE URINARY ELIMINATION OF IRON IN NORMAL AND PATHOLOGICAL SUBJECTS].
Topics: Anemia; Deferoxamine; Duodenal Ulcer; Hemochromatosis; Humans; Hydroxamic Acids; Hypersplenism; Iron | 1964 |
CONGENITAL ERYTHROBLASTIC HYPOPLASIA; TREATMENT OF TRANSFUSION HEMOSIDEROSIS WITH DESFERRIOXAMINE B.
Topics: Anemia; Anemia, Aplastic; Blood Group Incompatibility; Blood Transfusion; Deferoxamine; Hemosiderosi | 1964 |
[THE USE OF DESFERRIOXAMINE IN THE TREATMENT OF HEMOCHROMATOSIS].
Topics: Anemia; Anemia, Aplastic; Blood Chemical Analysis; Body Fluids; Deferoxamine; Hemochromatosis; Hydro | 1964 |
SUBSTITUTIVE-INHIBITORY THERAPY IN CONSTITUTIONAL NON-SPHEROCYTIC ERYTHROCYTIC DISEASE.
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Congenital Nonspherocytic; Blood Transfusion; Deferoxa | 1964 |
[A NEW TEST FOR ASCERTAINMENT OF STATES OF SIDEROSIS: THE DESFERRIOXAMINE TEST. PRELIMINARY RESULTS].
Topics: Anemia; Anemia, Hypochromic; Biomedical Research; Deferoxamine; Hematologic Diseases; Hemochromatosi | 1964 |
[CONGENITAL HYPOPLASTIC ANEMIA. REVIEW AND REPORT ON A CASE TREATED WITH DESFERRIOXAMINE B].
Topics: Anemia; Anemia, Aplastic; Anemia, Hypoplastic, Congenital; Deferoxamine; Humans; Hydroxamic Acids; I | 1964 |
EVALUATION OF DEFEROXAMINE IN IRON OVERLOAD.
Topics: Anemia; Deferoxamine; Humans; Iron; Iron Overload; Pentetic Acid; Pharmacology; Toxicology; Urine | 1964 |
[RESEARCH ON DESFERRIOXAMINE B. II. THE MECHANISM OF FERRO-CHELATION "IN VIVO" BY DESFERRIOXAMINE B].
Topics: Anemia; Anemia, Hypochromic; Deferoxamine; Erythrocytes; Hemochromatosis; Ions; Iron; Iron Isotopes; | 1964 |
[RESEARCH ON DESFERRIOXAMINE B. 3. THE CLINICAL USE OF DESFERRIOXAMINE B].
Topics: Anemia; Anemia, Hemolytic; Anemia, Macrocytic; Deferoxamine; Hematologic Diseases; Hemochromatosis; | 1964 |
TREATMENT OF PRIMARY AND SECONDARY HEMOCHROMATOSIS AND ACUTE IRON POISONING WITH A NEW POTENT IRON ELIMINATING AGENT (DESFERRIOXAMINE B-DFOM).
Topics: Anemia; Anemia, Aplastic; Anemia, Hemolytic; Anemia, Macrocytic; Deferoxamine; Guinea Pigs; Heavy Me | 1964 |
IRON DEFICIENCY ANAEMIA.
Topics: Anemia; Anemia, Hypochromic; Anemia, Iron-Deficiency; Deferoxamine; Drug Therapy; Hematologic Diseas | 1964 |
[DESFERRIOXAMINE (DF) AND DIETHYLENE TRIAMINE PENTA-ACETIC ACID TRISODIUM CALCIUM SALT (CA DTPA NA3) IN SIDEROSIS. 2].
Topics: Anemia; Anemia, Hypochromic; Blood Transfusion; Calcium; Chelating Agents; Deferoxamine; Drug Therap | 1965 |
DIFFERENTIAL FERRIOXAMINE TEST FOR MEASURING CHELATABLE BODY IRON.
Topics: Anemia; Anemia, Aplastic; Anemia, Hemolytic; Anemia, Iron-Deficiency; Anemia, Pernicious; Deferoxami | 1965 |
STUDIES ON DESFERRIOXAMINE IN RELATION TO THE ABSORPTION OF IRON.
Topics: Anemia; Anemia, Hypochromic; Deferoxamine; Hemochromatosis; Hemoglobins; Intestinal Absorption; Iron | 1965 |
IRON LOADING ANEMIA.
Topics: Anemia; Anemia, Hypochromic; Bloodletting; Deferoxamine; Drug Therapy; Hemochromatosis; Humans; Iron | 1965 |
CLINICAL STUDIES OF STORAGE IRON WITH DESFERRIOXAMINE.
Topics: Anemia; Anemia, Aplastic; Blood Transfusion; Deferoxamine; Drug Therapy; Feces; Humans; Iron; Urine | 1965 |
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update.
Topics: Aged; Anemia; Deferoxamine; Female; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Ov | 2004 |
[Bull's-Eye Maculopathy with Deferoxamine Treatment].
Topics: Aged; Anemia; Deferoxamine; Electroretinography; Erythrocyte Transfusion; Ferritins; Fluorescein Ang | 2004 |
Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
Topics: Anemia; Blood Transfusion; Chemical Fractionation; Child; Chromatography, Gel; Deferoxamine; Hemochr | 1999 |
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
Topics: Anemia; Blood Transfusion; Deferoxamine; Humans; Iron Chelating Agents; Primary Myelofibrosis | 2007 |
Nature of anaemia in rheumatoid arthritis. VII. Storage of iron in rheumatoid disease.
Topics: Adult; Anemia; Arthritis, Rheumatoid; Deferoxamine; Female; Hemoglobinometry; Humans; Iron; Male; Mi | 1967 |
[Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
Topics: Anemia; Deferoxamine; Female; Ferritins; Hemosiderosis; Heterozygote; HLA Antigens; HLA-A3 Antigen; | 1984 |
Increased storage of iron and anaemia in rheumatoid arthritis: usefulness of desferrioxamine.
Topics: Adult; Aged; Anemia; Arthritis, Rheumatoid; Deferoxamine; Female; Ferritins; Humans; Iron; Male; Mid | 1984 |
Vitamin C, desferrioxamine and iron loading anemias.
Topics: Anemia; Ascorbic Acid; Deferoxamine; Genes, Recessive; Hemochromatosis; Humans; Intestinal Absorptio | 1984 |
Anemia of inflammatory disease in the dog: availability of storage iron in inflammatory disease.
Topics: Anemia; Animals; Biological Availability; Deferoxamine; Dog Diseases; Dogs; Female; Ferritins; Hemos | 1981 |
Transfusion therapy: its role in the anemias.
Topics: Anemia; Blood Group Incompatibility; Blood Grouping and Crossmatching; Deferoxamine; Erythrocyte Tra | 1980 |
Treatment of iron storage disorders.
Topics: Anemia; Deferoxamine; Hemochromatosis; Humans; Iron; Liver Cirrhosis; Porphyrias; Skin Diseases; Tha | 1980 |
Mechanism of inhibitory effects of chelating drugs on lipid peroxidation in rat brain homogenates.
Topics: Adenosine Diphosphate; Anemia; Animals; Antioxidants; Brain; Deferoxamine; Edetic Acid; Electron Spi | 1994 |
Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
Topics: Aluminum; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Humans; Kidney Failure, Chronic; Mi | 1993 |
Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis.
Topics: Adolescent; Anemia; Child; Child, Preschool; Deferoxamine; Erythrocyte Transfusion; Ferritins; Hemoc | 1996 |
Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis.
Topics: Anemia; Arthritis, Rheumatoid; Chronic Disease; Deferoxamine; Dose-Response Relationship, Drug; Enzy | 1996 |
Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
Topics: Administration, Oral; Aluminum Compounds; Anemia; Animals; Bile; Chelating Agents; Deferoxamine; Kid | 1997 |
Prolonged macrophage activation and persistent anaemia in children with complicated malaria.
Topics: Analysis of Variance; Anemia; Antimalarials; Child, Preschool; Deferoxamine; Drug Therapy, Combinati | 1998 |
Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Colony-Forming Units Assay; Deferoxamine; Drug Synergism; Er | 1999 |
Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Topics: Anemia; Chelating Agents; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Ferritins; Humans; I | 1999 |
Association of phlebotomy and subcutaneous bolus injection of deferoxamine for the treatment of anemic patients with iron overload.
Topics: Anemia; beta-Thalassemia; Combined Modality Therapy; Deferoxamine; Female; Humans; Injections, Subcu | 2001 |
Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias.
Topics: Adolescent; Adult; Anemia; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Humans; Infusions, | 1978 |
Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.
Topics: Adult; Anemia; Chronic Disease; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents; | 1978 |
Lacoferrin in rabbit bile: its relation to iron metabolism.
Topics: Anemia; Animals; Bile; Deferoxamine; Hemoglobins; Iron; Lactoferrin; Lactoglobulins; Male; Rabbits; | 1975 |
Possible mechanisms underlying potentiating effects of iron chelators in hematopoietic response to erythropoietin.
Topics: Anemia; Deferoxamine; Drug Synergism; Erythropoietin; Hematopoiesis; Humans; Kidney Failure, Chronic | 1992 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Anemia; Bone Diseases, Metabolic; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failu | 1992 |
Effect of body iron stores on serum aluminum level in hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aluminum; Aluminum Hydroxide; Anemia; Deferoxamine; Female; Ferritins; Huma | 1992 |
Aluminum toxicity.
Topics: Aluminum; Anemia; Animals; Deferoxamine; Dementia; Disease Models, Animal; Humans; Kidney Failure, C | 1991 |
Desferrioxamine versus erythropoietin for treatment of dialysis anaemia.
Topics: Aluminum; Anemia; Deferoxamine; Erythropoietin; Humans; Renal Dialysis; Time Factors | 1990 |
Case management of the anemic patient epoetin alfa: focus on aluminum management.
Topics: Adult; Aged; Aluminum; Anemia; Deferoxamine; Erythropoietin; Female; Humans; Kidney Failure, Chronic | 1991 |
Aluminium interference in the treatment with recombinant human erythropoietin.
Topics: Aluminum; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Humans; Recombinant Proteins; Uremi | 1990 |
Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
Topics: Adult; Aluminum; Anemia; Deferoxamine; Erythropoietin; Humans; Middle Aged; Recombinant Proteins; Re | 1990 |
The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment.
Topics: Aluminum; Anemia; Biological Availability; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Hum | 1990 |
Trace elements and complications in patients undergoing chronic hemodialysis.
Topics: Aluminum; Anemia; Deferoxamine; Female; Hematocrit; Hemoglobins; Humans; Kidney Failure, Chronic; Ma | 1990 |
Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis.
Topics: Aluminum; Anemia; Deferoxamine; Hematopoiesis; Hemoglobins; Humans; Kidney Failure, Chronic; Prospec | 1989 |
The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
Topics: Aluminum; Ambulatory Care; Anemia; Biomarkers; Deferoxamine; Erythrocytes; Female; Humans; Male; Reg | 1989 |
Iron status in patients receiving erythropoietin for dialysis-associated anemia.
Topics: Anemia; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failure, Chronic; Recombinant Proteins; R | 1989 |
Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
Topics: Adult; Aluminum; Anemia; Deferoxamine; Erythrocyte Indices; Female; Ferritins; Hemoglobins; Humans; | 1988 |
Desferrioxamine, anaemia, and haemodialysis.
Topics: Adult; Anemia; Deferoxamine; Humans; Male; Renal Dialysis | 1988 |
Anaemia and aluminium chelation therapy in dialysis patients.
Topics: Aluminum; Anemia; Deferoxamine; Humans; Renal Dialysis | 1988 |
Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
Topics: Aluminum; Anemia; Deferoxamine; Erythrocytes; Ferritins; Humans; Peritoneal Dialysis, Continuous Amb | 1989 |
Improvement of anaemia with desferrioxamine in haemodialysis patients.
Topics: Adult; Aluminum; Anemia; Blood Transfusion; Deferoxamine; Female; Hematocrit; Hemosiderosis; Humans; | 1987 |
Desferrioxamine improves anaemia in haemodialysis patients without aluminum or iron overload.
Topics: Anemia; Deferoxamine; Female; Humans; Middle Aged; Renal Dialysis | 1988 |
Effect of desferrioxamine on anaemia of haemodialysis patients.
Topics: Anemia; Deferoxamine; Humans; Renal Dialysis | 1988 |
Desferrioxamine does not improve aluminium-unrelated anaemia of haemodialysis.
Topics: Adult; Anemia; Deferoxamine; Female; Humans; Male; Middle Aged; Renal Dialysis | 1988 |
Microcytic anemia in dialysis patients.
Topics: Aluminum; Anemia; Deferoxamine; Humans; Renal Dialysis | 1988 |
The response of the normochromic normocytic anaemia of chronic renal failure to desferrioxamine.
Topics: Adult; Aged; Aluminum; Anemia; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Femal | 1987 |
Iron mobilization from isolated hepatocytes.
Topics: Anemia; Animals; Apoproteins; Citrates; Deferoxamine; In Vitro Techniques; Iron; Iron Radioisotopes; | 1986 |
Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
Topics: Adult; Aluminum; Anemia; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamine; Erythrocyte | 1987 |
Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
Topics: Adult; Anemia; Blood Glucose; Deferoxamine; Glucose Tolerance Test; Hemosiderosis; Humans; Iron; Iro | 1985 |
Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
Topics: Aluminum; Anemia; Child; Deferoxamine; Epilepsies, Myoclonic; Humans; Kidney Failure, Chronic; Male; | 1985 |
High-dose desferoxamine and Diamond-Blackfan anemia.
Topics: Adolescent; Anemia; Deferoxamine; Heart Failure; Humans; Infusions, Parenteral; Thalassemia; Transfu | 1986 |
[Siderinuria caused by deferoxamine. II. The siderinuric increment obtained by association with ascorbic acid].
Topics: Adolescent; Adult; Aged; Anemia; Ascorbic Acid; Child, Preschool; Deferoxamine; Drug Therapy, Combin | 1973 |
[Urinary iron after desferrioxamine. I. Effectiveness and tolerance of high doses of the drug].
Topics: Adult; Aged; Anemia; Child, Preschool; Deferoxamine; Dose-Response Relationship, Drug; Female; Human | 1972 |
Site of action of desferrioxamine in removing iron in normal and pathological conditions.
Topics: Anemia; Animals; Brain Chemistry; Deferoxamine; Heart; Infusions, Parenteral; Iron; Iron-Dextran Com | 1974 |
[Disorders of iron metabolism in liver patients].
Topics: Adult; Anemia; Biopsy; Deferoxamine; Feces; Female; Hemochromatosis; Humans; Iron; Iron Isotopes; Li | 1966 |
[Desferal S and D tests in the diagnosis of anemias].
Topics: Adolescent; Adult; Anemia; Anemia, Hemolytic; Anemia, Hypochromic; Deferoxamine; Female; Humans; Mal | 1970 |
[Iron storage disease].
Topics: Adult; Anemia; Child; Deferoxamine; Female; Hemochromatosis; Humans; Iron; Liver Diseases; Male; Mid | 1967 |
Evaluation of storage iron by chelates.
Topics: Anemia; Animals; Bone Marrow; Deferoxamine; Feces; Hemochromatosis; Humans; Iron; Iron Isotopes; Liv | 1968 |
Hematological investigations in Ethiopia with special reference to a high iron intake.
Topics: Adolescent; Adult; Altitude; Anemia; Autopsy; Blood Sedimentation; Blood Specimen Collection; Body W | 1968 |
The chelation of iron during intestinal absorption.
Topics: Adult; Anemia; Anemia, Hypochromic; Biological Transport; Citrates; Deferoxamine; Humans; Injections | 1969 |
[Clinical and metabolic research on treatment with desferrioxamine B in various hemosiderotic erythrocyte diseases].
Topics: Adolescent; Adult; Aged; Anemia; Child; Child, Preschool; Deferoxamine; Female; Hemosiderosis; Human | 1965 |
The response of free erythrocyte protoporphyrin to pyridoxine therapy in a patient with sideroachrestic (sideroblastic) anemia.
Topics: Aged; Anemia; Blood Sedimentation; Deferoxamine; Erythrocytes; Hemoglobins; Humans; In Vitro Techniq | 1966 |